120
Participants
Start Date
April 9, 2018
Primary Completion Date
January 14, 2019
Study Completion Date
January 14, 2019
Influenza Multimeric-001 Vaccine
The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
Placebo
Placebo is saline injection
Quadrivalent Recombinant Seasonal Influenza Vaccine
Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
University of Iowa - Vaccine Research and Education Unit, Iowa City
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati
Baylor College of Medicine - Molecular Virology and Microbiology, Houston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH